Vitality Watch

⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.

Mentioned 1× · first seen 10-sep-2026 · last seen 10-sep-2026

TWEAK/Fn14 Signaling in Muscle Aging

Current understanding

TWEAK (TNFSF12) signaling through its receptor Fn14 is emerging as an inflammatory cytokine axis proposed to drive age-related skeletal muscle wasting by suppressing mitochondrial biogenesis and amplifying p38 MAPK-linked catabolic signaling. Preclinical C2C12 and aged-mouse AAV-knockdown work indicates TWEAK suppression enhances mitochondrial biogenesis via AMPK activation and attenuates age-related muscle mass loss, though a functional grip-strength benefit was not shown, keeping this at target-validation stage [animal-model]. No human translation exists; the mechanistic case is preclinical only and the standing area caveat about model-to-human translation applies.

Evidence log

Open questions

Related

Contributing findings

pubmed preclinical
Targeting TWEAK to enhance mitochondrial biogenesis and attenuate age-related muscle mass loss.
14-aug-2026 novelty 3 per-area 3 introduces

build build 880 · 2bcef25 · 2026-11-18